Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Select users in the Dev Channel and Beta Channel can now try AI actions in File Explorer and several other features. The latest Dev Channel update, which brings systems to Build 26200.5603 , also ...

Forbes contributors publish independent expert analyses and insights. I write about charitable giving and estate planning ideas.